CSPC Pharmaceutical Group Limited (HKG: 1093) announced in a voluntary announcement that it will present the latest updates from 8 clinical trials at the European Society for Medical Oncology (ESMO) Congress 2026, to be held in Madrid, Spain, from 23 to 27 October 2026. Two of the selected studies have been designated Late‑breaking Abstracts (LBA), underscoring the clinical significance of the data set to be disclosed.
Contents
ESMO 2026 Congress Snapshot
| Item | Detail |
|---|---|
| Company | CSPC Pharmaceutical Group Limited (HKG: 1093) |
| Congress | ESMO Congress 2026 – Madrid, Spain |
| Dates | 23–27 October 2026 |
| Total Presentations | 8 clinical trials: 1 Proffered Paper, 3 Rapid Oral, 3 Poster, 1 e‑Poster |
| Late‑Breaking Abstracts | 2 (LBA15, LBA80) |
| Tumour Types Covered | Breast, lung, gastric, liver, colorectal and pancreatic cancers, plus perivascular epithelioid cell tumour (PEComa) |
| Announcement Date | 5 October 2026 |
Presentation Line‑Up
| Abstract No. | Format | Asset | Study & Setting |
|---|---|---|---|
| LBA15 | Proffered Paper | Anbenitamab (Ennituo) + HB1801 | Phase III interim analysis – first‑line HER2‑positive advanced breast cancer |
| LBA80 | Rapid Oral | Anbenitamab (Ennituo) | Phase III updated overall survival – HER2‑positive advanced gastric/GEJ cancer |
| 5RO | Rapid Oral | SYS6043 (B7‑H3 ADC) | Phase I/II monotherapy – breast cancer results in advanced solid tumours |
| 1009RO | Rapid Oral | JMT108 (SYS6090) (anti‑PD‑1/IL‑15) | Phase I/II – liver and colorectal cancer results |
| 3743P | Poster | HB1901 (albumin‑bound sirolimus) | Phase Ib/III – advanced malignant PEComa |
| 1028P | Poster | SYS6023 (HER3 ADC) | Phase I/IIa monotherapy – advanced solid tumours |
| 2927P | Poster | JSKN003 (HER2 ADC) | Phase II combination – first‑line HER2‑positive gastric/GEJ adenocarcinoma |
| 3077eTiP | e‑Poster | HB1801 (ADOF regimen) | Phase Ib/III DAWN study vs. FOLFOX – first‑line advanced gastric/GEJ adenocarcinoma |
Drug Profile & Mechanism of Action
- Anbenitamab (Ennituo): A HER2 bispecific antibody co‑developed with Alphamab Oncology, binding two non‑overlapping HER2 epitopes to block signalling, enhance ADCC and CDC effects, and downregulate cell‑surface HER2. CSPC is the sole marketing authorisation holder (MAH) and trademark owner in the Chinese Mainland.
- HB1801 (Docetaxel, Albumin‑Bound): A nanomedicine‑platform product free of polysorbate 80 and ethanol — requiring no steroid premedication and enabling rapid high‑concentration infusion. It is the first modified chemotherapy formulation in China to receive Breakthrough Therapy Designation (BTD).
- SYS6043: A B7‑H3‑targeted ADC carrying a topoisomerase I inhibitor payload with a DAR of approximately 6, Fc‑silencing design and cleavable linker to enhance anti‑tumour activity while reducing off‑target toxicity.
- JMT108 (SYS6090): An anti‑PD‑1/IL‑15 asymmetric bifunctional Fc fusion protein — one arm blocks the PD‑1/PD‑L1 axis, the other activates IL‑15 receptor signalling — with a molecular design intended to limit systemic immune toxicity.
- SYS6023: A HER3 ADC whose topoisomerase I inhibitor payload is not a substrate for efflux pumps, a potential advantage over DXd‑payload ADCs in overcoming drug resistance.
- JSKN003 (Anbenitamab Repodatecan): A homogeneous, site‑specifically conjugated HER2 bispecific ADC (DAR 4) demonstrating better serum stability, reduced haematologic toxicity and a stronger bystander effect, expanding the therapeutic window.
- HB1901: An albumin‑bound sirolimus (mTOR inhibitor) nanoparticle designed to overcome the low bioavailability and GI toxicity of oral formulations; the PEComa study is the first randomised controlled trial in this rare tumour.
Regulatory & Clinical Milestones
| Item | Detail |
|---|---|
| NMPA Approval | Anbenitamab approved for marketing in May 2026 – second‑line and beyond HER2‑positive advanced gastric cancer (BTD + Priority Review) |
| NMPA BTD (July 2026) | Granted to both Anbenitamab and HB1801 – first‑line HER2‑positive advanced breast cancer |
| NDA Status | Two breast cancer NDAs for Anbenitamab (neoadjuvant + first‑line) accepted with Priority Review by the NMPA |
| FDA Designations | Anbenitamab: Orphan Drug (HER2‑positive/HER2‑low gastric cancer); JSKN003: Orphan Drug (GC/GEJ), Fast Track (PROC) and BTD (bevacizumab‑pretreated HER2‑expressing PROC) |
| NMPA BTD (Feb 2025) | HB1901 for advanced malignant PEComa |
| Trial Data | Efficacy and safety figures not yet disclosed – to be presented at ESMO Congress 2026 |
Market Impact & Outlook
- Oncology Franchise Depth: Eight presentations spanning seven tumour types demonstrate the breadth of CSPC’s in‑house R&D engine, from bispecific antibodies and ADCs to bifunctional immunotherapies and nanomedicine reformulations.
- Late‑Breaking Recognition: The selection of two LBAs — including a Proffered Paper for the first‑line HER2‑positive breast cancer Phase III — signals data of practice‑changing potential in one of oncology’s most competitive segments.
- Breast Cancer Leadership Strategy: CSPC has built a comprehensive neoadjuvant–adjuvant–first‑line development strategy for the Anbenitamab + HB1801 combination, with both Phase III studies having met their primary endpoints.
- ADC Platform Momentum: SYS6043 is entering pivotal Phase III studies in ovarian, breast and small cell lung cancer, while JSKN003 has multiple registrational studies ongoing across breast, ovarian and colorectal cancer.
- Commercial Readiness: As sole MAH in the Chinese Mainland for Anbenitamab and JSKN003, and leveraging an established commercialisation system, the Group is positioned to translate trial wins into market access rapidly.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial presentations, regulatory timelines, and commercial expectations for CSPC’s oncology pipeline. Actual results may differ due to risks including final data readouts at ESMO 2026, regulatory review outcomes, and competitive dynamics.-Fineline Info & Tech
